Related Experiment Video
Updated: May 6, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues
Franziska Hoschek1, Julia Natan1, Maximilian Wagner1
1Department of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Insights
Huntington disease (HD) involves a toxic HTT exon 1 fragment produced from the HTT1a RNA. This study confirms HTT1a expression correlates with CAG repeat length in human tissues, suggesting it as a potential disease marker.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Huntington disease (HD) is caused by a CAG trinucleotide expansion in the huntingtin (HTT) gene.
- This mutation leads to the production of a toxic HTT exon 1 protein fragment via the HTT1a RNA.
- Previous studies showed CAG repeat length dependency in mouse models, but human data were lacking.
Purpose of the Study:
- To quantify HTT1a RNA levels in human tissues.
- To determine the correlation between HTT1a expression and CAG repeat length in humans.
- To assess HTT1a as a potential biomarker for HD progression.
Main Methods:
- Development of sensitive digital PCR assays for absolute quantification of HTT1a transcripts.
- Measurement of CAG repeat sizes in all human samples.
- Statistical analysis using ANOVA and linear modeling to correlate HTT1a levels with CAG repeat length.
Main Results:
- HTT1a expression was confirmed in human post-mortem brain tissues and peripheral cell types.
- A statistically significant positive correlation between HTT1a expression and CAG repeat length was observed in PBMCs.
- Elevated HTT1a levels were detected in PBMCs even within the adult-onset CAG repeat range.
Conclusions:
- HTT1a is expressed across a wide range of human tissues and CAG repeat lengths.
- Peripheral samples demonstrate CAG repeat length-dependent HTT1a generation.
- HTT1a levels may serve as a sensitive marker for HD disease state and progression, valuable for clinical trials.
Background:
The disease-causing mutation in Huntington disease (HD) is a CAG trinucleotide expansion in the huntingtin (HTT) gene. The mutated CAG tract results in the production of a small RNA, HTT1a, coding for only exon 1 of HTT. HTT1a is generated by a block in the splicing reaction of HTT exon 1 to exon 2 followed by cleavage in intron 1 and polyadenylation. Translation of HTT1a leads to the expression of the highly toxic HTT exon 1 protein fragment. We have previously shown that the levels of HTT1a expression in mouse models of HD is dependent on the CAG repeat length. However, these data are lacking for human tissues.
Methods:
To answer this question, we developed highly sensitive digital PCR assays to determine HTT1a levels in human samples. These assays allow the absolute quantification of transcript numbers and thus also facilitate the comparison of HTT1a levels between tissues, cell types and across different studies. Furthermore, we measured CAG repeat sizes for every sample used in the study. Finally, we analysed our data with ANOVA and linear modelling to determine the correlation of HTT1a expression levels with CAG repeat sizes.
Results:
In summary, we show that HTT1a is indeed expressed in a CAG repeat-length-dependent manner in human post mortem brain tissues as well as in several peripheral cell types. In particular, PBMCs show a statistically significant positive correlation of HTT1a expression with CAG repeat length, and elevated HTT1a expression levels even in the adult-onset CAG repeat range.
Conclusions:
Our results show that HTT1a expression occurs throughout a wide range of tissues and likely with all CAG lengths. Our data from peripheral sample sources demonstrate that HTT1a is indeed generated throughout the body in a CAG repeat-length-dependent manner. Therefore, the levels of HTT1a might be a sensitive marker of disease state and/or progression and should be monitored over time, especially in clinical trials targeting HTT expression.
More Related Videos
11:22Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
Published on: June 27, 2018
10:52Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
Related Concept Videos
Histone Variants at the Centromere
Non-LTR Retrotransposons
lncRNA - Long Non-coding RNAs
Huntington Disease l: Introduction